# Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

> **NCT04526574** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1796 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
- **OTHER:** Saline
- **BIOLOGICAL:** Influenza vaccine

## Key facts

- **NCT ID:** NCT04526574
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 1796 (ACTUAL)
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526574, "Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04526574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*